Furthermore, the efficacy of EGFR‐targeted therapeutics in EGFRhigh/EpCAMlow carcinomas showing high Slug expression and high ERK1/2 phosphorylation levels [11] may profit from re‐evaluation. This evidence concerns the gene EGFR and carcinoma.